Objective: The CD155/TIGIT axis has attracted considerable interest as an emerging immune checkpoint with potential applications in cancer immunotherapy. Our research focused on investigating the role of CD155/TIGIT checkpoints in the progression of triple-negative breast cancer (TNBC). Methods: We evaluated CD155 and TIGIT expression in TNBC tissues using both immunohistochemistry (IHC) and gene expression profiling. Our experiments, both in vivo and in vitro, provided evidence that inhibiting the CD155/TIGIT pathway reinstates the ability of CD8 + T cells to generate cytokines. To assess the impact of CD155/TIGIT signaling blockade, we utilized Glucose Assay Kits and Lactate Assay Kits to measure alterations in glucose and lactate levels within CD8 + T cells. We employed western blotting (WB) to investigate alterations in glycolytic-related proteins within the PI3K/AKT/mTOR pathways following the inhibition of CD155/TIGIT signaling. Results: CD155 exhibits heightened expression within TNBC tissues and exhibits a negative correlation with the extent of infiltrating CD8 + T cells. Furthermore, patients with TNBC demonstrate elevated levels of TIGIT expression. Our findings indicate that the interaction between CD155 and TIGIT disrupts the glucose metabolism of CD8 + T cells by suppressing the activation of the PI3K/AKT/mTOR signaling pathway, ultimately leading to the reduced production of cytokines by CD8 + T cells. Both in vivo and in vitro experiments have conclusively demonstrated that the inhibition of CD155/TIGIT interaction reinstates the capacity of CD8 + T cells to generate cytokines. Moreover, in vivo administration of the blocking antibody against TIGIT not only inhibits tumor growth but also augments the functionality of CD8 + T lymphocytes. Conclusions: Our research findings strongly suggest that CD155/TIGIT represents a promising therapeutic target for treating TNBC.
In breast cancer (BC) patients with clinical axillary lymph node metastasis (cN+) undergoing neoadjuvant therapy (NAT), precise axillary lymph node (ALN) assessment dictates therapeutic strategy. There is a critical demand for a precise method to assess the axillary lymph node (ALN) status in these patients. A retrospective analysis was conducted on 160 BC patients undergoing NAT at Fujian Medical University Union Hospital. We analyzed baseline and two-cycle reassessment dynamic contrast-enhanced MRI (DCE-MRI) images, extracting 3668 radiomic and 4096 deep learning features, and computing 1834 delta-radiomic and 2048 delta-deep learning features. Light Gradient Boosting Machine (LightGBM), Support Vector Machine (SVM), RandomForest, and Multilayer Perceptron (MLP) algorithms were employed to develop risk models and were evaluated using 10-fold cross-validation. Of the patients, 61 (38.13 %) achieved ypN0 status post-NAT. Univariate and multivariable logistic regression analyses revealed molecular subtypes and Ki67 as pivotal predictors of achieving ypN0 post-NAT. The SVM-based "Data Amalgamation" model that integrates radiomic, deep learning features, and clinical data, exhibited an outstanding AUC of 0.986 (95 % CI: 0.954-1.000), surpassing other models. Our study illuminates the challenges and opportunities inherent in breast cancer management post-NAT. By introducing a sophisticated, SVM-based "Data Amalgamation" model, we propose a way towards accurate, dynamic ALN assessments, offering potential for personalized therapeutic strategies in BC.
This study developed a machine learning model for predicting the presence of tertiary lymphoid structures (TLSs) and treatment response to neoadjuvant therapy (NAT) in triple-negative breast cancer (TNBC). This multicenter study retrospectively included 697 patients, including the training cohort (n = 137), the TLS validation cohort (n = 63) and the NAT response validation cohorts (n = 560). Five machine learning models were developed to predict the presence of TLSs, and the XGBoost model, which exhibited the best performance, was selected as the radiomics-based TLS (rTLS) predictive model. The rTLS predictive model demonstrated robust predictive performance, including across various patient subgroups. Prognostic analysis showed that the rTLS predictive score was significantly correlated with disease-free survival (DFS) in TNBC receiving NAT, and was identified as a strong independent prognostic factor. Pathomic features further explained the pathological heterogeneity of TNBC with different responses to NAT. Overall, the rTLS predictive model, which accurately predicted the presence of TLSs and treatment response to NAT in TNBC, held promise for future clinical application in formulating personalized strategies for TNBC, ultimately improving prognosis, aiding in individualized patient treatment.
Metabolic reprogramming is a cornerstone of cancer cell adaptation to the demanding tumor microenvironment, requiring fine-tuned control over energy, lipid metabolism, and stress responses. Central to this adaptation is the profound and bidirectional interplay between two key cellular processes: lipid storage in lipid droplets (LDs) and cellular recycling via autophagy. LDs are dynamic organelles that have emerged as critical metabolic and signaling hubs, extending far beyond their role as simple lipid depots. Autophagy, a fundamental degradation system, supplies essential metabolites during stress by engulfing cellular material in autophagosomes. These pathways are deeply intertwined: LDs not only provide lipids and proteins for autophagosome formation but are also selectively targeted for degradation by autophagy in a process known as lipophagy. This degradation releases free fatty acids that fuel mitochondrial β-oxidation, enabling cancer cells to withstand hypoxic and nutrient-poor conditions. Moreover, lipophagy prevents lipotoxicity by eliminating excess lipids, thus maintaining cellular homeostasis. Here, we review the molecular mechanisms governing the LD-autophagy axis in cancer, discuss its pivotal roles in tumor progression, metastasis, and therapeutic resistance, and explore the promise of targeting this nexus for future cancer therapies. Unraveling this complex network provides not only a new paradigm for understanding cancer metabolism but also offers a compelling rationale for developing novel pharmacological agents to combat tumor metabolic plasticity and therapeutic resistance.
Background: Triple-negative breast cancer (TNBC) remains a clinical challenge due to its aggressiveness and limited therapeutic options. The tumor microenvironment (TME), particularly the extracellular matrix (ECM), is a critical regulator of TNBC progression, yet the key molecular drivers remain largely elusive. This study aimed to identify novel TME-related prognostic biomarkers and elucidate their functional roles in TNBC. Method: We constructed and validated a multi-gene prognostic model using TNBC datasets from Gene Expression Omnibus (GEO) and The Cancer Genome Atlas (TCGA) databases. The model’s association with TME characteristics was assessed using ESTIMATE algorithm and immune infiltration analyses. The biological functions of the key gene, Microfibril Associated Protein 4 (MFAP4), were investigated in vitro via proliferation and migration assays. The underlying mechanism was explored through Western blotting and validated by a functional rescue experiment using a PI3K/AKT/mTOR pathway agonist. Results: We established a robust 11-gene prognostic model that effectively stratified TNBC patients into high- and low-risk groups with distinct overall and metastasis-free survival. The low-risk group was characterized by an immune-active microenvironment. Notably, MFAP4, an ECM-related gene within the signature, was identified as a key tumor suppressor. MFAP4 expression was significantly downregulated in TNBC tissues and correlated with worse prognosis. Overexpression of MFAP4 markedly suppressed TNBC cell proliferation and migration. Mechanistically, MFAP4 inhibited the phosphorylation of key components of the PI3K/AKT/mTOR pathway. Crucially, pharmacological activation of this pathway with MHY1485 partially rescued the anti-tumor effects induced by MFAP4. Conclusion: Our study established a TME-centric prognostic signature and, more importantly, identified MFAP4 as a novel tumor suppressor in TNBC. We provide the first evidence that MFAP4 inhibits TNBC malignancy by restraining the PI3K/AKT/mTOR signaling pathway, thereby establishing a critical link between the ECM and intracellular oncogenic signaling. MFAP4 represents a promising prognostic biomarker and a potential therapeutic target for TNBC.